Dermatology

Nemolizumab is an anti-IL-31Rα monoclonal antibody that has demonstrated clinical efficacy in two global Phase III studies (ARCADIA-1 and…

​​Epigenetic changes drive skin aging by silencing the expression of youthful genes. Experts discussed the discovery of epicelline, an…

​​A review highlighting the need to improve vitiligo care through understanding the role of the JAK-STAT pathway, early diagnosis and…

​Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based on…

Psoriasis symptoms can be not only uncomfortable, irritating, and painful, but can also impact several aspects of a patients’ daily life…

Due to the clinical heterogenicity of HS, assessment of disease severity is complex, and over 20 different outcome measures have…

Vitiligo is an autoimmune skin disorder that causes depigmentation of the skin and/or leukotrichia of the hair, resulting from the…

During this symposium, global experts in dermatology gave a series of lectures focused on skin treatments and their benefits for patients…

This review of the ‘Elevating Aesthetics’ symposium held at the International Master Course on Aging Science (IMCAS) 2023 shares insights…

This year’s European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Tumours Group (CLTG) Annual Meeting was held in Madrid, Spain. Presentations covered a broad range of topics in the field of cutaneous lymphomas, from molecular mechanisms, through diagnostics and prediction of prognosis, to skin-directed and targeted therapies, combination therapies, and patient-reported outcomes.

Sun exposure can lead to tanning, but also to skin damage due to the actions of ultraviolet A and B, visible light, and infrared radiation. One result of sun exposure is field cancerisation (FC), the precursor to actinic keratosis (AK), which in turn is a risk factor for, most notably, squamous cell carcinoma.

Chronic spontaneous urticaria (CSU) is characterised by the spontaneous occurrence of wheals (hives) and/or angioedema for ≥6 weeks.1 CSU can persist for several years and is associated with severe pruritus. Skin mast cell activation in CSU occurs via Type I autoallergy driven by IgE to autoallergens, and a Type IIb autoimmune response due to mast cell-targeted autoantibodies against IgE or high-affinity IgE receptor.

The primary endpoint analyses from the SUNSHINE and SUNRISE Phase III trials of secukinumab in moderate-to-severe hidradenitis suppurativa (HS) were featured in an oral presentation as part of the late-breaking news session at the 31st annual European Academy of Dermatology and Venereology (EADV) congress. Known collectively as the SUNNY trials, the SUNSHINE and SUNRISE studies represent the largest Phase III trials conducted in HS to date.

Any filler injection requires a bespoke treatment approach and a thorough anatomy knowledge to minimise procedural risks and achieve…

The solar spectrum is composed of various wavelengths of electromagnetic radiation that can penetrate the skin to different levels: the longer…

The latest research on autoimmune skin disease has studied the efficacy and safety characterisation of guselkumab (GUS), a human monoclonal…

Strober began by summarising his opinion on the key characteristics of anti-IL-23 therapies that support their efficacy for inducing…

The latest international guidelines on urticaria were published in September as a joint initiative from the European Academy of…

Recent years have witnessed significant advances in the understanding of facial anatomy. Extensive studies have uncovered the arrangement of soft-tissue layers underlying the skin and their mobility during expression. Meanwhile, increasing awareness of the facial vascular network has laid the foundation for lower risk cosmetic procedures.

Richard B. Warren highlighted Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the Phase III BE VIVID trial in patients…

In the late-breaking research sessions, Reich presented BE RADIANT, the first Phase III trial to compare inhibition of IL-17A and IL-17F…

This Janssen-sponsored live satellite symposium, entitled ‘Where do we begin? The key role of the IL-23 pathway in psoriasis and psoriatic…

Pioneering global best practices in atopic dermatitis (AD) and implementing them in the clinic are important steps towards optimising patient care…

Eczematous dermatitis (or eczema) includes AD, CD, and DD. This inflammatory skin reaction presents as erythema, vesicles, desquamation…

Atopic dermatitis (AD), sometimes referred to as ‘atopic eczema’, is a common, chronic, pruritic, Type II inflammatory skin disease which is associated…

The indicative scaly, erythematous plaques of plaque psoriasis arise because of abnormal interactions between immune system cells and epidermal…

Terrestrial solar UVR consists of UVA (320–400 nm) and UVB (280–320 nm; typically around 295–320nm because of attenuation by the ozone…

Psoriasis, a chronic systemic inflammatory disease with skin manifestations, can be an impediment to daily life. Accordingly…

Prof Reich began by highlighting how insights into the pathophysiology of psoriasis have led to the development and expansion of cytokine-targeted…

The VOYAGE 1 trial1 was a placebo- and active-controlled Phase III study to evaluate long-term efficacy and safety of the IL-23p19 inhibitor guselkumab…

Psoriasis is a Th17-driven disease, with both IL-17A and IL-17F playing a pivotal role in its pathogenesis.2,3 BKZ is a monoclonal IgG1 antibody…

An enhanced understanding of real-world CL Gel usage could help improve the management of patients with MF-CTCL…

MF-CTCL is a rare type of cutaneous non-Hodgkin’s lymphoma where uncontrolled growth of the pathological skin-homing T-lymphocytes results first in skin…

Advances in the treatment of moderate-to-severe psoriasis have accelerated considerably in the last 30 years. Prof Piaserico provided an overview of the…

Psoriasis is a chronic, relapsing inflammatory skin disease, characterised in most cases by sharply demarcated, erythematous, pruritic plaques covered…

IL-23 plays a key regulatory role in the pathogenesis of plaque psoriasis and medications targeting IL-23 have been shown to be effective for people with…

Development of psoriasis occurs due to interactions with epidermal keratinocytes and immune-system cells including T-lymphocytes, antigen-presenting…

Psoriasis is associated with high morbidity, causing problems in daily life such as itching and scaling, even for patients with less-severe disease…

Allergies represent a significant, rising health concern. Recent figures indicate that 150 million Europeans experience chronic allergic disease…

The symposium “IL-23 Inhibition: From Pathophysiological Jungle to Clinical Clearance” took place during the 2019 annual European Academy of Dermatology…

Guselkumab was the first monoclonal antibody targeting the p19 subunit of IL-23 (IL-23p19) to be approved for the treatment of psoriasis.

Prof Augustin opened the symposium by underlining how the management of patients with moderate-to-severe atopic dermatitis (AD) has become more dynamic…

Psoriasis and AD are chronic, systemic inflammatory diseases of the skin characterised by upregulation of proinflammatory cytokines…

The objectives of this symposium were to understand the importance of planning treatment addressing the specific needs of women living…

Type 2 immunity evolved from a dialogue between the immune system and microbes. This form of immunity confers protection against bacteria, viruses…

Prof Schaller posed the question “what makes rosacea so special?” and explained that the manifestations of rosacea are very varied, including papules…

Psoriasis occurs more frequently alongside other IMID, indicating common pathogenetic pathways. Many of these IMID show familial accumulation…

The fumarates, monoethyl fumarate (MEF) and dimethyl fumarate (DMF), are potent ester derivatives of fumaric acid. Fumaric acid esters (FAE)…

This sponsored symposium took place on 12th June 2019 in Milan, Italy, as part of the 24th World Congress of Dermatology (WCD), 2019

This symposium took place on 13th June 2019, as part of the World Congress of Dermatology (WCD) symposium in Milan, Italy

Prof Elke de Jong focussed her presentation on data from randomised clinical trials (RCT) and real-world evidence (RWE) from psoriasis patient registries.

Dermatologists frequently see psoriasis patients for whom the most troublesome symptoms are not the constant physical discomfort…

Affecting up to 11.4% of the population worldwide, psoriasis is one of the most common chronic autoinflammatory diseases.

The goal of this programme is to support dermatologists to improve the management of patients with moderate-to-severe AD and bring together clinicians…

This presentation by Dr Weisenseel considered the role of fumaric acid esters (FAE) in plaque psoriasis.

The rising incidence of CSCC presents a major challenge for healthcare systems and the frequency and impact of progression to advanced disease is…